Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07551583 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07551583: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07551583 is a Phase 2 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07551583, a Phase 2 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
Interventions
- DRUG Nivolumab
- DRUG Doxorubicin Hydrochloride
- DRUG Dacarbazine
- DRUG Vinblastine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2032-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07551583
The ClinicalTrials.gov registry entry for NCT07551583 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT07551583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07551583 about?
NCT07551583 is a clinical study titled "Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL". The goal of this clinical research study is to learn if nivolumab plus AVD (doxorubicin, vinblastine, and dacarbazine) can help to control newly diagnosed early-stage non-bulky cHL in pediatric, adolescent, and young adult patients. The safety of this drug combination will also be studied.
What is the current status of trial NCT07551583?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-10-01. Estimated completion is 2032-12-31.
What interventions are being tested in trial NCT07551583?
The interventions under investigation include: Nivolumab (DRUG), Doxorubicin Hydrochloride (DRUG), Dacarbazine (DRUG), Vinblastine (DRUG).
Who is sponsoring clinical trial NCT07551583?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.